197 related articles for article (PubMed ID: 35042096)
21. Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125 556 patients.
Heikkinen M; Taipale H; Tanskanen A; Mittendorfer-Rutz E; Lähteenvuo M; Tiihonen J
Addiction; 2021 Aug; 116(8):1990-1998. PubMed ID: 33394527
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal stability of reward and relief drinking phenotypes in community and treatment-seeking individuals who engage in heavy drinking.
Hebden HM; Swan JE; Claus ED; Pentkowski NS; Witkiewitz K
Alcohol Clin Exp Res (Hoboken); 2024 Mar; 48(3):567-579. PubMed ID: 38311341
[TBL] [Abstract][Full Text] [Related]
23. Rationale for combining acamprosate and naltrexone for treating alcohol dependence.
Mason BJ
J Stud Alcohol Suppl; 2005 Jul; (15):148-56; discussion 140. PubMed ID: 16223066
[TBL] [Abstract][Full Text] [Related]
24. Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review.
Hyland CJ; McDowell MJ; Bain PA; Huskamp HA; Busch AB
J Subst Abuse Treat; 2023 Jan; 144():108919. PubMed ID: 36332528
[TBL] [Abstract][Full Text] [Related]
25. Advances in Pharmacotherapy Development: Human Clinical Studies.
Litten RZ; Falk DE; Ryan ML; Fertig J; Leggio L
Handb Exp Pharmacol; 2018; 248():579-613. PubMed ID: 29294197
[TBL] [Abstract][Full Text] [Related]
26. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.
Mann K; Lemenager T; Hoffmann S; Reinhard I; Hermann D; Batra A; Berner M; Wodarz N; Heinz A; Smolka MN; Zimmermann US; Wellek S; Kiefer F; Anton RF;
Addict Biol; 2013 Nov; 18(6):937-46. PubMed ID: 23231446
[TBL] [Abstract][Full Text] [Related]
27. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis.
McPheeters M; O'Connor EA; Riley S; Kennedy SM; Voisin C; Kuznacic K; Coffey CP; Edlund MD; Bobashev G; Jonas DE
JAMA; 2023 Nov; 330(17):1653-1665. PubMed ID: 37934220
[TBL] [Abstract][Full Text] [Related]
28. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
Richardson K; Baillie A; Reid S; Morley K; Teesson M; Sannibale C; Weltman M; Haber P
Addiction; 2008 Jun; 103(6):953-9. PubMed ID: 18482418
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological treatment of alcohol dependence: a review of the evidence.
Garbutt JC; West SL; Carey TS; Lohr KN; Crews FT
JAMA; 1999 Apr; 281(14):1318-25. PubMed ID: 10208148
[TBL] [Abstract][Full Text] [Related]
30. Reward and relief craving tendencies in patients with alcohol use disorders: results from the PREDICT study.
Glöckner-Rist A; Lémenager T; Mann K;
Addict Behav; 2013 Feb; 38(2):1532-1540. PubMed ID: 23148916
[TBL] [Abstract][Full Text] [Related]
31. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
[TBL] [Abstract][Full Text] [Related]
32. Does family history of alcoholism moderate naltrexone's effects on alcohol use?
Capone C; Kahler CW; Swift RM; O'Malley SS
J Stud Alcohol Drugs; 2011 Jan; 72(1):135-40. PubMed ID: 21138720
[TBL] [Abstract][Full Text] [Related]
33. Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging.
Mann K; Vollstädt-Klein S; Reinhard I; Leménager T; Fauth-Bühler M; Hermann D; Hoffmann S; Zimmermann US; Kiefer F; Heinz A; Smolka MN
Alcohol Clin Exp Res; 2014 Nov; 38(11):2754-62. PubMed ID: 25421512
[TBL] [Abstract][Full Text] [Related]
34. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
Rösner S; Leucht S; Lehert P; Soyka M
J Psychopharmacol; 2008 Jan; 22(1):11-23. PubMed ID: 18187529
[TBL] [Abstract][Full Text] [Related]
35. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment.
Rubio G; Jiménez-Arriero MA; Ponce G; Palomo T
Alcohol Alcohol; 2001; 36(5):419-25. PubMed ID: 11524308
[TBL] [Abstract][Full Text] [Related]
36. Medications for Alcohol Use Disorder.
Poorman E; McQuade BM; Messmer S
Am Fam Physician; 2024 Jan; 109(1):71-78. PubMed ID: 38227873
[TBL] [Abstract][Full Text] [Related]
37. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.
Morley KC; Teesson M; Reid SC; Sannibale C; Thomson C; Phung N; Weltman M; Bell JR; Richardson K; Haber PS
Addiction; 2006 Oct; 101(10):1451-62. PubMed ID: 16968347
[TBL] [Abstract][Full Text] [Related]
38. New pharmacotherapies for alcohol dependence.
Graham R; Wodak AD; Whelan G
Med J Aust; 2002 Jul; 177(2):103-7. PubMed ID: 12098353
[TBL] [Abstract][Full Text] [Related]
39. Acamprosate: recent findings and future research directions.
Mann K; Kiefer F; Spanagel R; Littleton J
Alcohol Clin Exp Res; 2008 Jul; 32(7):1105-10. PubMed ID: 18540918
[TBL] [Abstract][Full Text] [Related]
40. Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials.
Falk DE; Litten RZ; Anton RF; Kranzler HR; Johnson BA;
J Stud Alcohol Drugs; 2014 Mar; 75(2):335-46. PubMed ID: 24650828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
